We utilize our proprietary computational target discovery platform to identify novel drug targets and pathways and develop first-in-class therapeutics designed to address the unmet need in cancer immunotherapy. Our drug and clinical development processes are guided by a deep understanding of the biology of these novel pathways to identify optimal drug combinations and design a robust biomarker strategy for patient selection.

Compugen's Pipeline Program



COM701 / PVRIG COM701 + Opdivo COM701 + Opdivo + BMS-986207 COM902 / TIGIT Multiple myeloid programs BAY 1905254 BAY 1905254 + Keytruda Bi-specific products


Max 1mb, accepted formats: pdf, doc, docx, rtf
[recaptcha size:compact]
Message Sent. Thank You!